ERC Starting Grant · 2016
PREcision medicine Drug combination testing In neuroblastoma organoids to guide Clinical Trials
Neuroblastoma are pediatric tumors that respond poorly to chemotherapy and have a very poor prognosis. To improve treatment options, a global development towards precision medicine is ongoing. This strongly focusses on molecular genetic target identification in tumors and subsequent assigning patients to the best trials according to their molecular profile. Still it is difficult to predict which patients will benefit from these targeted compounds. In addition, if tumors do respond to single compound targeted therapy, they almost always relapse. These tumor evolution processes could be prevented by simultaneous intervention in different activated tumor pathways. We now want to study how we…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.